K. Carroll, H. Ross, D. Evans, L. France, R. Hemmings et al., Conditional approval: discussion points from the PSI conditional approval expert group, Pharmaceutical Statistics, vol.254, issue.20, pp.263-269, 2008.
DOI : 10.1002/pst.309

R. Richesson and K. Vehik, Patient Registries: Utility, Validity and Inference, Adv Exp Med Biol, vol.686, pp.87-104, 2010.
DOI : 10.1007/978-90-481-9485-8_6

B. Poorthuis, R. Wevers, W. Kleijer, J. Groener, J. De-jong et al., The frequency of lysosomal storage diseases in The Netherlands, Human Genetics, vol.105, issue.1-2, pp.151-156, 1999.
DOI : 10.1007/s004399900075

P. Meikle, J. Hopwood, A. Clague, and W. Carey, Prevalence of Lysosomal Storage Disorders, JAMA, vol.281, issue.3, pp.249-254, 1999.
DOI : 10.1001/jama.281.3.249

R. Pinto, C. Caseiro, M. Lemos, L. Lopes, A. Fontes et al., Prevalence of lysosomal storage diseases in Portugal, European Journal of Human Genetics, vol.12, issue.2, pp.87-92, 2004.
DOI : 10.1038/sj.ejhg.5201044

M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan et al., High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*, The American Journal of Human Genetics, vol.79, issue.1, pp.31-40, 2006.
DOI : 10.1086/504601

S. Jones, E. James, and S. Prasad, Disease Registries and Outcomes Research in Children, Pediatric Drugs, vol.144, issue.1, pp.33-47, 2011.
DOI : 10.2165/11586860-000000000-00000

R. Desnick, Y. Ioannou, C. Eng, C. Scriver, A. Beaudet et al., alpha-Galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease, pp.3733-3774, 2001.

S. Rombach, T. Twickler, J. Aerts, G. Linthorst, F. Wijburg et al., Vasculopathy in patients with Fabry disease: Current controversies and research directions, Molecular Genetics and Metabolism, vol.99, issue.2, pp.99-108, 2010.
DOI : 10.1016/j.ymgme.2009.10.004

R. Schiffmann, J. Kopp, H. Austin, S. Sabnis, D. Moore et al., Enzyme Replacement Therapy in Fabry Disease, JAMA, vol.285, issue.21, pp.2743-2749, 2001.
DOI : 10.1001/jama.285.21.2743

C. Eng, N. Guffon, W. Wilcox, D. Germain, P. Lee et al., Safety and Efficacy of Recombinant Human ??-Galactosidase A Replacement Therapy in Fabry's Disease, New England Journal of Medicine, vol.345, issue.1, pp.9-16, 2001.
DOI : 10.1056/NEJM200107053450102

P. Deegan, A. Baehner, B. Romero, M. Hughes, D. Kampmann et al., Natural history of Fabry disease in females in the Fabry Outcome Survey, Journal of Medical Genetics, vol.43, issue.4, pp.347-352, 2006.
DOI : 10.1136/jmg.2005.036327

W. Wilcox, J. Oliveira, R. Hopkin, A. Ortiz, M. Banikazemi et al., Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry, Molecular Genetics and Metabolism, vol.93, issue.2, pp.112-128, 2008.
DOI : 10.1016/j.ymgme.2007.09.013

C. Wanner, J. Oliveira, A. Ortiz, M. Mauer, D. Germain et al., Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry, Clinical Journal of the American Society of Nephrology, vol.5, issue.12, pp.2220-2228, 2010.
DOI : 10.2215/CJN.04340510

A. Mehta, J. Clarke, R. Giugliani, P. Elliott, A. Linhart et al., Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey, Journal of Medical Genetics, vol.46, issue.8, pp.548-552, 2009.
DOI : 10.1136/jmg.2008.065904

URL : https://hal.archives-ouvertes.fr/hal-00552689

A. Linhart, C. Kampmann, J. Zamorano, G. Sunder-plassmann, M. Beck et al., Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey, European Heart Journal, vol.28, issue.10, pp.1228-1235, 2007.
DOI : 10.1093/eurheartj/ehm153

U. Ramaswami, C. Whybra, R. Parini, G. Pintos-morell, A. Mehta et al., Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey, Acta Paediatrica, vol.34, issue.1, pp.86-92, 2006.
DOI : 10.1080/08035250500275022

M. Beck, R. Ricci, U. Widmer, F. Dehout, A. De-lorenzo et al., Fabry disease: overall effects of agalsidase alfa treatment, European Journal of Clinical Investigation, vol.327, issue.12, pp.838-882, 2004.
DOI : 10.1161/hs0202.102601

A. Mehta, M. Beck, P. Elliott, R. Giugliani, A. Linhart et al., Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data, The Lancet, vol.374, issue.9706, pp.1986-1996, 2009.
DOI : 10.1016/S0140-6736(09)61493-8

S. Rombach, M. Baas, I. Ten-berge, R. Krediet, F. Bemelman et al., The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease, Nephrology Dialysis Transplantation, vol.25, issue.8, pp.2549-2556, 2010.
DOI : 10.1093/ndt/gfq108

M. Connock, A. Juarez-garcia, E. Frew, A. Mans, J. Dretzke et al., A systematic review of the clinical effectiveness and costeffectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1, Health Technol Assess, vol.10, pp.1-130, 2006.

F. Breunig, F. Weidemann, J. Strotmann, A. Knoll, and C. Wanner, Clinical benefit of enzyme replacement therapy in Fabry disease, Kidney International, vol.69, issue.7, pp.1216-1221, 2006.
DOI : 10.1038/sj.ki.5000208

A. Vedder, G. Linthorst, G. Houge, J. Groener, E. Ormel et al., Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg, PLoS ONE, vol.115, issue.7, p.598, 2007.
DOI : 10.1371/journal.pone.0000598.s003

F. Weidemann, M. Niemann, F. Breunig, S. Herrmann, M. Beer et al., Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment, Circulation, vol.119, issue.4, pp.524-529, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.794529

E. Beutler, G. Grabowski, C. Scriver, A. Beaudet, W. Sly et al., Gaucher Disease In The Metabolic and Molecular Bases of Inherited Disease, pp.3635-3668, 2001.

E. Beutler, The cost of treating Gaucher disease, Nature Medicine, vol.47, issue.5, pp.523-524, 1996.
DOI : 10.1016/S0140-6736(95)91037-9

N. Weinreb, J. Charrow, H. Andersson, P. Kaplan, E. Kolodny et al., Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry, The American Journal of Medicine, vol.113, issue.2, pp.112-119, 2002.
DOI : 10.1016/S0002-9343(02)01150-6

J. Charrow, B. Dulisse, G. Grabowski, and N. Weinreb, The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease, Clinical Genetics, vol.104, issue.Suppl. 1, pp.205-211, 2007.
DOI : 10.1111/j.1399-0004.2007.00769.x

H. Andersson, P. Kaplan, K. Kacena, and Y. J. , Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1, PEDIATRICS, vol.122, issue.6, pp.1182-1190, 2008.
DOI : 10.1542/peds.2007-2144

G. Grabowski, K. Kacena, J. Cole, C. Hollak, L. Zhang et al., 36. Dose???response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type I, Molecular Genetics and Metabolism, vol.93, issue.2, pp.92-100, 2009.
DOI : 10.1016/j.ymgme.2007.10.048

M. Connock, A. Burls, E. Frew, . Fry-smith, A. Juarez-garcia et al., The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review, Health Technology Assessment, vol.10, issue.24, pp.1-136, 2006.
DOI : 10.3310/hta10240

T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. Van-weely et al., Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, The Lancet, vol.355, issue.9214, pp.1481-1486, 2000.
DOI : 10.1016/S0140-6736(00)02161-9

C. Hollak, S. Dahl, J. Aerts, N. Belmatoug, B. Bembi et al., Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease, Blood Cells, Molecules, and Diseases, vol.44, issue.1, pp.41-47, 2010.
DOI : 10.1016/j.bcmd.2009.09.006